Document Detail

Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis.
MedLine Citation:
PMID:  1446494     Owner:  NLM     Status:  MEDLINE    
The efficacy of ofloxacin, rifampicin and isoniazid was prospectively compared with the regimen of ethambutol, rifampicin and isoniazid for the primary treatment of pulmonary tuberculosis in 124 patients. All drugs were given orally daily for nine months. Culture conversion rates three months after starting treatment were 98 percent in the ofloxacin group and 94 percent in the ethambutol group; by six months all patients in both groups were culture-negative. Significant radiological improvement of pulmonary infiltrates was observed in 83 percent of the ofloxacin group and 85 percent of the ethambutol group one year after starting treatment. No relapse in either group was observed during a two-year follow-up period after the cessation of chemotherapy. Ofloxacin appears to be as useful as ethambutol in the treatment of pulmonary tuberculosis when either drug is combined with isoniazid and rifampicin.
S Kohno; H Koga; M Kaku; S Maesaki; K Hara
Related Documents :
19436614 - A controlled, randomized nonblinded clinical trial to assess the efficacy of amphoteric...
7873824 - Clinical experience with short schedules of itraconazole in the treatment of tinea corp...
6298584 - Severe chronic mucocutaneous candidiasis. favourable response to oral therapy with keto...
9763724 - Compliance with artesunate and quinine + tetracycline treatment of uncomplicated falcip...
1894294 - Restenosis after successful coronary angioplasty in single vessel disease.
19504094 - Total therapy-based treatment for multiple myeloma-a single center experience.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Chest     Volume:  102     ISSN:  0012-3692     ISO Abbreviation:  Chest     Publication Date:  1992 Dec 
Date Detail:
Created Date:  1992-12-29     Completed Date:  1992-12-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0231335     Medline TA:  Chest     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1815-8     Citation Subset:  AIM; IM    
Second Department of Internal Medicine, Nagasaki University School of Medicine, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Drug Combinations
Drug Resistance, Microbial
Ethambutol / administration & dosage,  adverse effects,  therapeutic use*
Isoniazid / administration & dosage,  therapeutic use
Middle Aged
Mycobacterium tuberculosis / drug effects,  isolation & purification
Ofloxacin / administration & dosage,  adverse effects,  therapeutic use*
Prospective Studies
Rifampin / administration & dosage,  therapeutic use
Time Factors
Tuberculosis, Pulmonary / drug therapy*,  microbiology
Reg. No./Substance:
0/Drug Combinations; 13292-46-1/Rifampin; 54-85-3/Isoniazid; 74-55-5/Ethambutol; 82419-36-1/Ofloxacin
Comment In:
Chest. 1994 May;105(5):1624   [PMID:  8181387 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Human pleural effusions are rich in matrix metalloproteinases.
Next Document:  Diagnostic value of sialic acid in malignant pleural effusions.